#USA #Irvine #PeproMene Bio #PMB-CT01 #EHA 2026

PeproMene Bio's Exciting Breakthrough in B-cell Lymphoma Treatment

Overview

In a significant announcement from Irvine, California, PeproMene Bio, Inc. has revealed that updated clinical data from their ongoing Phase 1 study on PMB-CT01, an innovative CAR T-cell therapy aimed at the BAFF-R, will be presented at the European Hematology Association (EHA) 2026 Congress. This groundbreaking therapy is currently being evaluated for patients with relapsed and refractory B-cell lymphomas, even after previous treatment failures with CD19-targeted CAR T-cells.

Promising Clinical Results

The Phase 1 study included nine patients who previously experienced treatment failures. PMB-CT01 demonstrated a notably favorable safety profile, with no dose-limiting toxicities or severe cytokine release syndrome (SCLS). Impressively, seven out of the nine patients—approximately 78%—achieved a complete response, marking a crucial milestone in this clinical trial. As of the last data cutoff, all responding patients maintained their remission; the longest duration without relapse exceeded three years. Moreover, patients showed negative minimal residual disease status, indicating a robust elimination of cancer cells.

Expansion Cohorts and Future Directions

Following these encouraging initial results, PeproMene is actively recruiting participants for expanded cohorts focusing on mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma. Of particular interest is the case of the first patient treated in the expansion phase—a patient who had previously progressed after CD19 CAR T-cell therapy and has since achieved a complete remission in their first disease evaluation. The significance of these findings cannot be understated, as they highlight the potential of PMB-CT01 in treating aggressive forms of lymphoma, where established treatment options are often limited.

The Medical Significance of BAFF-R Targeting

Dr. Larry W. Kwak, the scientific founder of PeproMene Bio, emphasized the considerable unmet medical need for patients whose cancer progresses after traditional CD19 therapy. The durable complete responses observed in the study validate BAFF-R as a promising new therapeutic target. Additionally, the favorable safety profile suggests that PMB-CT01 could eventually be viable for outpatient treatment settings and may warrant exploration for use in refractory autoimmune diseases.

Presentation Details

The details of the presentation at EHA 2026 are as follows:

• - Title: Durable Responses and Favorable Safety of BAFF-R CAR T-cells (PMB-CT01) in Patients with Relapsed/Refractory B-cell Lymphomas Post-prior CD19 Therapy or CD19-negative Disease
• - Abstract Number: EHA-1611 S287
• - Date/Time: June 14, 2026, from 11:00 AM to 12:15 PM CEST
• - Presenter: Dr. Larry W. Kwak, M.D., Ph.D.

About PMB-CT01

PMB-CT01 is distinguished as the first CAR T-cell therapy targeting BAFF-R, designed to be utilized in ongoing clinical trials for relapsed/refractory B-cell lymphoma and acute lymphoblastic leukemia. The BAFF-R receptor’s high expression exclusively on B-cells makes it an ideal target, reducing the likelihood of antigen escape, a common issue in cancer immunotherapy.

About PeproMene Bio

PeproMene Bio, Inc. is a clinical-stage biotechnology company based in Irvine, California. The company is committed to developing innovative therapies aimed at cancer and immune system disorders. For further inquiries, interested parties can contact Dr. Hazel Cheng at email protected] or visit [PeproMene Bio's website.

The prospect of a new treatment paradigm for B-cell lymphoma is on the horizon, and PeproMene Bio's ongoing research could play a pivotal role in transforming patient outcomes in this challenging area of oncology.